Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.62 |
| ▸ | TYMP | P19971 | 5/20 | 0.53 |
| ▸ | PYGM | P11217 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19407964 | 1.00 | TK2 (0.62) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL24229287 | 1.00 | TK2 (0.62) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL27915600 | 1.00 | TK2 (0.62) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL50826 | 1.00 | TK2 (0.62) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL5219823 | 0.91 | TK2 (0.55) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL5219815 | 0.91 | TK2 (0.55) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL15434595 | 0.91 | TK2 (0.55) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL16940274 | 0.91 | TK2 (0.55) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL5502489 | 0.91 | TK2 (0.67) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL5502493 | 0.91 | TK2 (0.67) | TK2TYMPPYGMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 735 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606584-B2 | Process for the preparation of oligonucleotides using modified oxidation protocol | HOFFMANN-LA ROCHE INC. (US) | 2026-04-21 | — | — | US | disclosed |
| WO-2025242321-A1 | NOVEL USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025242771-A1 | NOVEL USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20250197820-A1 | NUCLEIC ACID POLYMERASE AND ITS USE IN PRODUCING NON-DNA NUCLEOTIDE POLYMERS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-06-19 | — | — | US | disclosed |
| CN-118265782-A | Nucleic acid polymerase | 英国研究与创新组织 | 2024-06-28 | — | — | CN | disclosed |
| CN-113993876-B | Method for preparing oligonucleotides using improved oxidation scheme | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11859186-B2 | Antisense oligonucleotides useful in treatment of Pompe disease | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2024-01-02 | — | — | US | disclosed |
| US-20230322843-A1 | Process for the preparation of oligonucleotides using modified oxidation protocol | HOFFMANN-LA ROCHE INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230295207-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES USING MODIFIED OXIDATION PROTOCOL | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-115996935-A | Method for preparing oligonucleotides using improved oxidation scheme | 豪夫迈·罗氏有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20030219895-A1 | An oligonucleotide or a hybrids for encoding a protein kinase | ISIS PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030212017-A1 | Antisense modulation of farnesyl transferase beta subunit expression | ISIS PHARMACEUTICALS INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030211606-A1 | Antisense modulation of DYRK4 expression | ISIS PHARMACEUTICALS INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20030198965-A1 | Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression | ISIS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| US-6624294-B2 | Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside | ISIS PHARMACEUTICALS, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | IONIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | disclosed |
| US-6403779-B1 | DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION | ISIS PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-6277982-B1 | REACTING CARBOHYDRATE, OLIGONUCLEOTIDE, NUCLEOTIDE OR NUCLEOSIDE WITH CYCLIC SULFATE; PRODUCTION OF OLIGONUCLEOTIDES WITH IMPROVED HYBRIDIZATION AFFINITY AND NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295207-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES USING MODIFIED OXIDATION PROTOCOL | POLN, POLRMT, POLR2E | TK2 51/4885TYMP 20/4885PYGM 638/4885 |
| US-20230322843-A1 | Process for the preparation of oligonucleotides using modified oxidation protocol | POLRMT, POLB, POLM | TK2 25/4885TYMP 10/4885PYGM 694/4885 |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | TK2 447/4885TYMP 37/4885PYGM 2644/4885 |
| US-12606584-B2 | Process for the preparation of oligonucleotides using modified oxidation protocol | POLRMT, RNGTT, TRMT1 | TK2 47/4885TYMP 57/4885PYGM 1459/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | TK2 447/4885TYMP 37/4885PYGM 2644/4885 |
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | NSUN2, NT5C3B, RNGTT | TK2 203/4885TYMP 34/4885PYGM 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.